Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583209 | 0.95 | EDNRA (0.64) | EDNRAEDNRB | |
| SCHEMBL6581782 | 0.92 | EDNRA (0.59) | EDNRAEDNRB | |
| SCHEMBL6581264 | 0.86 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL6581778 | 0.83 | EDNRA (0.54) | EDNRAEDNRB | |
| SCHEMBL6654039 | 0.81 | EDNRA (0.83) | EDNRAEDNRB | |
| SCHEMBL6579232 | 0.77 | EDNRA (0.44) | EDNRAEDNRB | |
| SCHEMBL795169 | 0.74 | EDNRA (0.88) | EDNRAEDNRB | |
| SCHEMBL4070379 | 0.73 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL7207974 | 0.72 | EDNRA (0.64) | EDNRAEDNRB | |
| SCHEMBL7210039 | 0.70 | EDNRA (0.62) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1191026-B1 | New pyridazine endothelin antagonists | PFIZER LTD (GB) | 2004-05-19 | — | — | EP | claimed |
| US-6670362-B2 | Treatment of restenosis, acute or chronic renal failure, pulmonary hypertension, systemic hypertension, benign prostatic hyperplasia, male erectile dysfunction, prostate cancer, metastatic bone cancer, angina, atherosclerosis | PFIZER INC. | 2003-12-30 | — | — | US | claimed |
| US-20020061889-A1 | New pyridazine endothelin antagonists | PFIZER INC. | 2002-05-23 | — | — | US | claimed |
| EP-1191026-A1 | New pyridazine endothelin antagonists | Pfizer Limited (GB) | 2002-03-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061889-A1 | New pyridazine endothelin antagonists | EDNRB, EDNRA, ECE1 | EDNRA 2/4885EDNRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.